


# Innovation at UC Berkeley

The Office of Intellectual Property and Industry Research Alliances (IPIRA), is UC Berkeley's premier organization for industry contacts and relationships. We have established agreements with nearly 1,000 companies, and we have relationships with thousands of investors, entrepreneurs, researchers, attorneys, faculty and students. IPIRA leverages its vast industry network to maximize the success of Berkeley's research collaborations and commercialization partnerships, as well as incubation, funding and mentorship.


Subscribe to Newsletter  
[www.ipira.berkeley.edu/newsletter](http://www.ipira.berkeley.edu/newsletter)

Access Concierge Service  
[www.ipira.berkeley.edu/concierge](http://www.ipira.berkeley.edu/concierge)

- Life Sciences
- Electronics and Hardware
- Materials
- Information Technology
- Cleantech and Energy



## BERKELEY'S IMPACT



197+ startup companies were founded to commercialize inventions and software under licenses from IPIRA



600+ products and services have been commercialized by companies with IP licenses from Berkeley



29 startups have had successful exits via merger or acquisition, totalling

\$8.1B in cash and stock options



66 Berkeley startups currently in the Bay Area employ

1,543 Californians, generating


\$195M in annual revenue



\$1.6B in VC funding attracted by Berkeley startups (2005-2016), and

\$51M in SBIR/STTR grants

Backed by a vibrant startup culture that is an engine of economic growth for the Bay Area and beyond, UC Berkeley has numerous programs that support the translation of university research into real-world solutions. For the past decade, IPIRA has helped Berkeley's entrepreneurs develop over 600 products, and we have supported campus innovators through the formation of 4 industry-sponsored institutes including the Innovative Genomics Initiative and the Immunotherapeutics and Vaccine Research Initiative..



The Innovative Genomics Initiative (IGI) led by Executive Director Jennifer Doudna, is dedicated to the enhancement and proliferation of genome editing research and technology, together with its application towards fundamental discovery and translational application. The IGI collaborates with academic and industrial research partners worldwide in order to expand our understanding and promote the use and development of CRISPR-Cas9 technology.



The Immunotherapeutics and Vaccine Research Initiative (IVRI) is a center for basic and early applied research in immunology, microbial pathogenesis, and vaccinology. The initiative is founded on the principle that mechanistic research investigating the role of the immune system in infectious disease yields new approaches for treating cancer, and conversely, that studies of cancer immunology yield approaches for vaccines and therapies targeting infectious disease.



The Joint BioEnergy Institute (JBEI) is a U.S. Department of Energy (DOE) bioenergy research center dedicated to developing advanced biofuels—liquid fuels derived from the solar energy stored in plant biomass that can replace gasoline, diesel, and jet fuels. Inside JBEI's Emeryville laboratories, researchers are using the latest tools in molecular biology, chemical engineering, computational and robotic technologies to transform biomass into fuels.